Search in:

Advanced search

Expert Opinion on Drug Safety Volume 7, 2008 - Issue 6

Submit an article Journal homepage

165

Views

CrossRef citations to date

Altmetric

Drug Safety Evaluation

Safety of peginterferon in the treatment of chronic hepatitis C

Nikroo Hashemi Fellow Thomas Jefferson University, Division of Gastroenterology and Hepatology, Philadelphia, PA, USA

, MD MPH,

Simona Rossi Clinical Assistant Professor of Medicine Thomas Jefferson University, Division of Gastroenterology and Hepatology, Philadelphia, PA, USA

, MD,

Victor J Navarro Professor of Medicine, Medical Director for Liver Transplantation Thomas Jefferson University, Division of Gastroenterology and Hepatology, Philadelphia, PA, USA

, MD &

Steven K Herrine Professor of Medicine Thomas Jefferson University, Division of Gastroenterology and Hepatology, Philadelphia, PA, USA +1 215 955 8900; +1 215 503 2146; [email protected]

, MD

Pages 771-781 | Published online: 04 Nov 2008

Cite this article
https://doi.org/10.1517/14740330802423291

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Davis FF, Abuchowski A, Van Es T. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng 1978;4:169-73
Google Scholar
He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of tricosanthin by site-directed pegylation. Life Sci 1999;65:355-68
PubMed Web of Science ®Google Scholar
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2-b plus ribavirin compared with interferon alfa 2-b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
PubMed Web of Science ®Google Scholar
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
PubMed Web of Science ®Google Scholar
Wills RJ. Clinical Pharmacology of interferons. Clin Pharmacokinet 1990;19:390-9
PubMed Web of Science ®Google Scholar
Gale M Jr. Effector genes of interferon action against hepatitis C virus. Hepatology 2003;37:975-8
PubMed Web of Science ®Google Scholar
Sen GC. Viruses and interferons. Ann Rev Microbiol 2001;55:255-81
PubMed Web of Science ®Google Scholar
Meyer Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alfa-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006;13:457-65
PubMed Web of Science ®Google Scholar
Tilg H. New insights into the mechanisms of interferon: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21
PubMed Web of Science ®Google Scholar
Haria M, Benfield P. Interferon-alfa-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995;50:873-96
PubMed Web of Science ®Google Scholar
Smith RA, Norris F, Palmer D, et al. Distribution of alfa interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985;37:85-8
PubMed Web of Science ®Google Scholar
Peg-Intron® (peginterferon alfa-2b) package insert. Kelinworth, NJ: Schering Corporation; 2005. Available from: http://www.spfiles.com/pipeg-intron.pdf [Last accessed June 2008]
Google Scholar
Pegasys® (peginterferon alfa-2a) package insert. Nutley, NJ: Hoffmann-La Roche Inc.; 2002. Available from: http://pegasys.com/hcp/default.aspx [Last accessed June 2008]
Google Scholar
Harrison's Online. Part 13: Disorders of the Gastrointestinal System. Section 2: Liver and Biliary Tract Disease, Chapter 300. Chronic Hepatitis. Available from: http://www.accessmedicine.com/content.aspx?aID=2876243&searchStr=peginterferon [Last accessed July 2008]
Google Scholar
Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81
PubMed Web of Science ®Google Scholar
Di Marco V, Almasio PL, Ferraro D, et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91
PubMed Web of Science ®Google Scholar
Abergel A, Hezode C, Leroy V, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alfa-2b. J Viral Hepat 2006;13:811-20
PubMed Web of Science ®Google Scholar
Linsday K, Trepo C, Heintegs T, et al. A randomized, double-blind trial comparing pegylated interferon alfa 2-b to interferon alfa 2-b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
PubMed Web of Science ®Google Scholar
Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7
PubMed Web of Science ®Google Scholar
Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67
PubMed Web of Science ®Google Scholar
Milkiewicz P, Yim C, Pache I, et al. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005;19:677-8
PubMed Web of Science ®Google Scholar
Manjón-Haces JA, Vázquez-López F, Gómez-Díez S, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol 2001;8:223
Google Scholar
Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alfa 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007;34:577-82
PubMed Web of Science ®Google Scholar
Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alfa-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-9
PubMed Web of Science ®Google Scholar
Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C. A series of 20 patients. Br J Dermatol 2002;147:1142-6
PubMed Web of Science ®Google Scholar
Kartal ED, Alpat SN, Ozgunes I, et al. Reversible alopecia universalis secondary to PEG-interferon alfa-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007;19:817-2
PubMed Web of Science ®Google Scholar
Taliani G, Biliotti E, Capanni M, et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. Chemotherapy 2005;17:212-4
Web of Science ®Google Scholar
Demirturk N, Aykin N, Demirdal T, et al. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006;16:579-80
PubMed Web of Science ®Google Scholar
Stryjek-Kaminska D, Ochsendorf F, Roder C, et al. Photoallergic skin reaction to ribavirin. Am J Gastroenterol 1999;94:1686-8
PubMed Web of Science ®Google Scholar
Sookoian S, Neglia V, Castano G, et al. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999;135:1000-1
PubMed Web of Science ®Google Scholar
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44
PubMed Web of Science ®Google Scholar
Balan V, Schwartz D, Wu GY, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005;100:299-307
PubMed Web of Science ®Google Scholar
Kowdley KV. Hematologic side effects of interferon and ribavirin therapy [review]. J Clin Gastroenterol 2005;39(Suppl 1):S3-8
PubMed Web of Science ®Google Scholar
Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alfa-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-7
PubMed Web of Science ®Google Scholar
Dar Santos AE, Partovi N, Ford JA, et al. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007;41:268-75
PubMed Web of Science ®Google Scholar
Koliouskas D, Didiropoulos I, Masmanidou M, et al. Comparative analysis and effect of GM-CSF on neutropenia in peg-interferon alfa-2b and ribavirin-treated chronic hepatitis C patients [abstract]. Hepatology 2002;36:587A
Google Scholar
Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alfa. Gastroenterol Clin Biol 1998;22:353-7
PubMed Web of Science ®Google Scholar
Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alfa plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41-8
PubMed Web of Science ®Google Scholar
Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alfa (IFN alfa) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-46
PubMed Web of Science ®Google Scholar
Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82(2):175-90
PubMed Web of Science ®Google Scholar
Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alfa in patients affected by hepatitis C virus. J Affect Disord 2002;72(3):237-41
PubMed Web of Science ®Google Scholar
Janssen HL, Brouwer JT, Van Der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3
PubMed Web of Science ®Google Scholar
Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57:531-6
PubMed Web of Science ®Google Scholar
Kraus MR, Schäfer A, Csef H. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11:1769-74
PubMed Web of Science ®Google Scholar
Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-14
PubMed Web of Science ®Google Scholar
Bagheri H, Fouladi K, Barange A, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004;24:1546-53
PubMed Web of Science ®Google Scholar
Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005;66:1050-7
PubMed Web of Science ®Google Scholar
Kalyoncu OA, Tan D, Mirsal H, et al. Major depressive disorder with psychotic features induced by interferon-alfa treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005;19:102-5
PubMed Web of Science ®Google Scholar
Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alfa treatment of hepatitis C. Addiction 2000;95:1101-4
PubMed Web of Science ®Google Scholar
Basanth KK, Jacob R, Jacob KS. Mania associated with interferon alfa2b treatment. J Postgrad Med 2006;52:207-9
PubMed Web of Science ®Google Scholar
Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-51
PubMed Web of Science ®Google Scholar
Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alfa and ribavirin: response and psychiatric side effects. Hepatology 2007;46(4):991-8
PubMed Web of Science ®Google Scholar
Geppert CM, Arora S. Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders. Hepatology 2007;46:957-9
PubMed Web of Science ®Google Scholar
Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006;101:2254-62
PubMed Web of Science ®Google Scholar
Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alfa associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-8
PubMed Web of Science ®Google Scholar
Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alfa-induced depression in patients with hepatitis C. J Affect Disord 2007;103:83-90
PubMed Web of Science ®Google Scholar
Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-7
PubMed Web of Science ®Google Scholar
Bacon BR. Managing hepatitis C [review]. Am J Manag Care 2004;10(Suppl 2):S30-40
PubMed Web of Science ®Google Scholar
Leung Y, Urbanski SJ, Schindel L, et al. Ischemic colitis during pegylated interferon-alfa and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol 2006;20:661-3
PubMed Web of Science ®Google Scholar
Punnam SR, Pothula VR, Gourineni N, et al. Interferon-ribavirin-associated ischemic colitis. J Clin Gastroenterol 2008;42:323-5
PubMed Web of Science ®Google Scholar
Tada H, Saitoh S, Nakagawa Y, et al. Ischemic colitis during interferon-alfa treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582-4
PubMed Web of Science ®Google Scholar
Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis 2007;13:1189-90
PubMed Web of Science ®Google Scholar
Watanabe T, Inoue M, Harada K, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alfa-2b and ribavirin. Gut 2006;55:1682-3
PubMed Web of Science ®Google Scholar
Cecchi E, Forte P, Cini E, et al. Pancreatitis induced by pegylated interferon alfa-2b in a patient affected by chronic hepatitis C. Emerg Med Australas 2004;16:473-5
PubMedGoogle Scholar
Ozdogan O, Tahan V, Cincin A, et al. Acute pancreatitis associated with the use of peginterferon. Pancreas 2007;34:485-7
PubMed Web of Science ®Google Scholar
Thurairajah PH, Thorburn D, Hubscher S, et al. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1293-300
PubMed Web of Science ®Google Scholar
Kuwata A, Ohashi M, Sugiyama M, et al. A case of reversible dilated cardiomyopathy after alfa-interferon therapy in a patient with renal cell carcinoma. Am J Med 2002;324:331-4
Google Scholar
Kruit WH, Punt KJ, Goey SH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alfa-interferon. An unexpectedly frequent complication. Cancer 1994;74:2850-6
PubMed Web of Science ®Google Scholar
Teragawa H, Hondo T, Amano H, et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996;37:905-15
PubMedGoogle Scholar
Condat B, Asselah T, Zanditenas D, et al. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:287-9
PubMed Web of Science ®Google Scholar
Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-40
PubMed Web of Science ®Google Scholar
Renou C, Germain S, Harafa A, et al. Interstitial pneumonia recurrence during chronic hepatitis C treatment. Am J Gastroenterol 2005;100:1625-6
PubMed Web of Science ®Google Scholar
Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007;30:92-7
PubMedGoogle Scholar
Doyle MK, Berggren R, Magnus JH. Interferon-induced sarcoidosis. J Clin Rheumatol 2006;12:241-8
PubMed Web of Science ®Google Scholar
Prummel MF, Laurberg P. Interferon-alfa and autoimmune thyroid disease. Thyroid 2003;13:547-51
PubMed Web of Science ®Google Scholar
Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alfa-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431-7
PubMed Web of Science ®Google Scholar
Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alfa therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403
PubMed Web of Science ®Google Scholar
Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10
PubMed Web of Science ®Google Scholar
Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alfa: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002;251:400-6
PubMed Web of Science ®Google Scholar
Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 2005;51:55-61
PubMedGoogle Scholar
Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006;21:319-26
PubMed Web of Science ®Google Scholar
Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004;164:2371-6
PubMed Web of Science ®Google Scholar
Eibl N, Gschwantler M, Ferenci P, et al. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alfa. Eur J Gastroenterol Hepatol 2001;13:295-8
PubMed Web of Science ®Google Scholar
Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alfa-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-92
PubMed Web of Science ®Google Scholar
Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008;28:39-46
PubMed Web of Science ®Google Scholar
Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58
PubMed Web of Science ®Google Scholar
Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-13
PubMed Web of Science ®Google Scholar
Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alfa-interferon treatment in chronic viral hepatitis. Hepatology 1998;27:1421-7
PubMed Web of Science ®Google Scholar
Manesis EK, Petrou C, Brouzas D, et al. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994;21:474-7
PubMed Web of Science ®Google Scholar
Andrade RJ, González FJ, Vázquez L, et al. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther 2006;11(4):491-8
PubMed Web of Science ®Google Scholar
Neubauer AS, Hoops JP. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2002;109:821-2
PubMedGoogle Scholar
Guyer DR, Tiedman J, Yannuzzi La, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-60
PubMed Web of Science ®Google Scholar
Yan KK, Dinihan I, Freiman J, et al. Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C. Intern Med J 2008;38(3):207-10
PubMed Web of Science ®Google Scholar
Lodato F, Tame MR, Colecchia A, et al. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006;12:4253-5
PubMed Web of Science ®Google Scholar
Deutsch M, Manesis EK, Hadziyannis E, et al. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scand J Gastroenterol 2007;42:408-9
PubMed Web of Science ®Google Scholar
Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int 1995;10:193-4
PubMedGoogle Scholar
Sulkowski M, Lawitz E. Shiffman ML, et al. Final results of the IDEAL (Individualized Dosing Efficacy versus flat dosing to Assess optimal pegylated interferon therapy) Phase IIIB study. J Hepatology 2008;48:S991
Google Scholar
Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7
PubMed Web of Science ®Google Scholar
Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
PubMed Web of Science ®Google Scholar
Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34
PubMed Web of Science ®Google Scholar
Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93
PubMed Web of Science ®Google Scholar
National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 June 10 – 12. HIV Clin Trials 2003;4:55
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Safety of peginterferon in the treatment of chronic hepatitis C

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety of peginterferon in the treatment of chronic hepatitis C

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date